TABLE 1.
Baseline characteristics and survival situation.
| Characteristics | n | Overall survival (%) | ||
|---|---|---|---|---|
| 1 year | 3 year | 5 year | ||
| Sex | ||||
| Male | 522 (62.7%) | 97.7 | 87.2 | 76.1 |
| Female | 311 (37.3%) | 96.5 | 83.9 | 79.7 |
| Age (years) | ||||
| ≤65 | 540 (64.8%) | 98.9 | 88.4 | 82.1 |
| >65 | 293 (35.2%) | 94.3 | 81.5 | 68.9 |
| BMI a | ||||
| <18.5 kg*m2‐1 | 42 (5.3%) | 92.9 | 72.8 | — |
| 18.5–23.5 kg*m2‐1 | 364 (46.2%) | 96.9 | 86.3 | 77 |
| >23.5 kg*m2‐1 | 381 (48.5%) | 97.9 | 87.2 | 78.9 |
| Preoperative radiochemotherapy | ||||
| No | 811 (97.4%) | 97.3 | 86.2 | 77.6 |
| Yes | 22 (2.6%) | — | 77.1 | 64.2 |
| HTN | ||||
| No | 573 (68.8%) | 97.4 | 86.3 | 78.6 |
| Yes | 260 (31.2%) | 96.9 | 85.3 | 74.9 |
| DM | ||||
| No | 720 (86.4%) | 97.8 | 86.9 | 79.1 |
| Yes | 113 (13.6%) | 94 | 80.4 | — |
| CHD | ||||
| No | 779 (93.5%) | 97.3 | 86.1 | 77.2 |
| Yes | 54 (6.5%) | 97.3 | 85.9 | 79 |
| COPD | ||||
| No | 799 (95.9%) | 97.4 | 86.4 | 77.8 |
| Yes | 34 (4.1%) | 95.1 | 75.8 | — |
| History of stroke | ||||
| No | 746 (89.5%) | 97.4 | 86.3 | 78.7 |
| Yes | 87 (10.5%) | 95.4 | 84.3 | 66.4 |
| Anemia | ||||
| No | 687 (82.5%) | 97.4 | 86.6 | 78.4 |
| Yes | 146 (17.5%) | 96.6 | 84 | 73.6 |
| Albumin | ||||
| <40 g*L‐1 | 238 (28.6%) | 94.9 | 81.5 | 71.9 |
| ≥40 g*L‐1 | 595 (71.4%) | 98.1 | 87.8 | 79.6 |
| AST | ||||
| Normal | 787 (94.5%) | 97.4 | 86.2 | 78.3 |
| Abnormal | 46 (5.5%) | 94.5 | 82.8 | 60.9 |
| DBIL b | ||||
| 0–6 μmol*L‐1 | 730 (90.2%) | 97.9 | 86.5 | 78.3 |
| >6 μmol*L‐1 | 79 (9.8%) | 92.1 | 82.9 | 73.1 |
| ASA | ||||
| 2 | 705 (84.6%) | 98 | 88.4 | 79.2 |
| 3 | 126 (15.1%) | 94.8 | 73.6 | 67.9 |
| 4 | 2 (0.3%) | — | — | — |
| The type of operation | ||||
| Laparoscopic surgery | 731 (87.8%) | 98.1 | 88 | 79.9 |
| Open surgery | 102 (12.2%) | 91.3 | 71.3 | 60.3 |
| TNM stage | ||||
| Stage 0–I | 169 (20.3%) | 99.2 | 97.6 | 94.6 |
| Stage II | 336 (40.3%) | 98 | 92 | 84.2 |
| Stage III | 295 (35.4%) | 95.6 | 79.3 | 65.9 |
| Stage IV | 33 (4%) | 92.8 | 27 | — |
| Histological type | ||||
| Adenocarcinoma | 775 (93%) | 97.3 | 87.1 | 78.5 |
| Mucinous | 45 (5.4%) | 97.7 | 80.7 | 75.7 |
| Others | 13 (1.6%) | 84.7 | 37.2 | 25.8 |
| Histologic grade | ||||
| Well | 66 (7.9%) | 98 | 97 | 89.8 |
| Moderate | 551 (66.1%) | 97.3 | 86.9 | 77.9 |
| Poorly | 170 (20.5%) | 95.8 | 79.4 | 70.2 |
| Unknown | 46 (5.5%) | 97.6 | 80.4 | 72.4 |
| Location | ||||
| Colon | 355 (42.6%) | 95.5 | 84.1 | 76 |
| Rectum | 478 (57.3%) | 98.5 | 87.4 | 78.5 |
| Tumor size | ||||
| ≤5 cm | 597 (71.7%) | 97.3 | 86.6 | 78.2 |
| >5 cm | 236 (28.3%) | 97 | 84.3 | 75.9 |
| CEA | ||||
| ≤5 ng*mL‐1 | 450 (54%) | 98.9 | 92.8 | 87.1 |
| >5 ng*mL‐1 | 290 (34.8%) | 96.7 | 79.6 | 67 |
| Unknown | 93 (11.2%) | 90.5 | 73.2 | 62 |
| CA19‐9 | ||||
| ≤37 U*mL‐1 | 644 (77.3%) | 98.6 | 90 | 82.4 |
| >37 U*mL‐1 | 89 (10.7%) | 93.6 | 70.2 | 57.4 |
| Unknown | 100 (12.0%) | 91.1 | 73.7 | 62.9 |
| Postoperative adjuvant chemotherapy | ||||
| No | 285 (34.2%) | 94.4 | 80.1 | 72.3 |
| Yes | 548 (65.8%) | 98.6 | 89.1 | 80.1 |
| RDW | ||||
| <13.5% | 580 (69.6%) | 97.6 | 88.3 | 80.6 |
| ≥13.5% | 253 (30.4%) | 96.4 | 80.7 | 70.2 |
| ΔRDW | ||||
| <0.9% | 615 (73.8%) | 97.9 | 89.6 | 82.1 |
| ≥0.9% | 218 (26.2%) | 95.4 | 76.2 | 64.3 |
| RDW | 13 (12.6–13.6) | 97.3 | 86 | 77.5 |
| ΔRDW | 0.3 (−0.2–0.9) | |||
| White blood cells (109*L‐1) | 6.2 (5.3–7.6) | |||
| Neutrophil (109*L‐1) | 3.8 (3.0–4.9) | |||
| Platelets (109*L‐1) | 236 (199.3–283) | |||
| MCV | 89.4 (86.1–92.2) | |||
| MPV | 10.5 (9.9–11.1) | |||
Note: Continuous data are presented as median (IQR).
Abbreviations: —, Survival rates are not shown because of the small cases; ASA, American society of anesthesiologists; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; MCV, mean corpuscle volume; MPV, mean platelet volume; RDW, red cell distribution width.
a
46 patients were missing.
b
24 patients were missing.